Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 639,173
  • Shares Outstanding, K 70,705
  • Annual Sales, $ 76,010 K
  • Annual Income, $ -118,670 K
  • 60-Month Beta 1.18
  • Price/Sales 8.47
  • Price/Cash Flow N/A
  • Price/Book 1.51
Trade ZYME with:

Options Overview Details

View History
  • Implied Volatility 148.43% ( +83.25%)
  • Historical Volatility 41.63%
  • IV Percentile 99%
  • IV Rank 76.62%
  • IV High 182.17% on 05/06/24
  • IV Low 37.86% on 10/06/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 1.17
  • Today's Open Interest 2,567
  • Open Int (30-Day) 2,000

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate 1.13
  • Low Estimate -0.48
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +86.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.31 +8.78%
on 05/31/24
9.90 -8.69%
on 06/12/24
+0.04 (+0.44%)
since 05/14/24
3-Month
7.97 +13.43%
on 04/26/24
10.98 -17.67%
on 03/21/24
-1.73 (-16.06%)
since 03/14/24
52-Week
6.01 +50.29%
on 10/04/23
13.14 -31.20%
on 02/27/24
+0.71 (+8.52%)
since 06/14/23

Most Recent Stories

More News
InMed Pharmaceuticals (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal,...

INM : 0.2267 (-4.55%)
QBTS : 1.1400 (+3.64%)
ZYME : 9.04 (-0.77%)
Zymeworks to Join NASDAQ Biotech Index

Zymeworks Inc. (NASDAQ: ZYME) gained ground Friday, as the clinical-stage biotechnology company developing ...

ZYME : 9.04 (-0.77%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 103.94 (-0.43%)
RY.TO : 142.87 (-0.38%)
ONCY : 1.0200 (-0.97%)
ONC.TO : 1.40 (unch)
JAZZ : 112.91 (+0.19%)
ZYME : 9.04 (-0.77%)
AMGN : 298.62 (+0.04%)
PTGX : 33.39 (-2.79%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

/PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer...

ONC.TO : 1.40 (unch)
ONCY : 1.0200 (-0.97%)
ZYME : 9.04 (-0.77%)
JAZZ : 112.91 (+0.19%)
PTGX : 33.39 (-2.79%)
AMGN : 298.62 (+0.04%)
Pioneering Cancer Treatments Show Promising Progress Despite Fiscal Challenges

USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer...

RY : 103.94 (-0.43%)
RY.TO : 142.87 (-0.38%)
ONCY : 1.0200 (-0.97%)
ONC.TO : 1.40 (unch)
JAZZ : 112.91 (+0.19%)
ZYME : 9.04 (-0.77%)
AMGN : 298.62 (+0.04%)
PTGX : 33.39 (-2.79%)
2 Biotech Stocks That Could Make You Richer

These biotech companies are seeing a spike in revenue growth.

VYGR : 8.51 (-3.30%)
ZYME : 9.04 (-0.77%)
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...

JAZZ : 112.91 (+0.19%)
ZYME : 9.04 (-0.77%)
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 42.19% and 307.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 9.04 (-0.77%)
HALO : 49.50 (-0.24%)
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

REGN : 1,036.52 (+0.97%)
ZYME : 9.04 (-0.77%)
Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 9.04 (-0.77%)
RARE : 39.05 (-9.44%)

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 9.41
2nd Resistance Point 9.29
1st Resistance Point 9.16
Last Price 9.04
1st Support Level 8.91
2nd Support Level 8.79
3rd Support Level 8.66

See More

52-Week High 13.14
Fibonacci 61.8% 10.42
Fibonacci 50% 9.58
Last Price 9.04
Fibonacci 38.2% 8.74
52-Week Low 6.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar